Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C99172
http://purl.obolibrary.org/obo/NCIT_C99172
|
|---|---|
| Preferred Name | Miransertib |
| Definitions |
An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Miransertib binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. This may lead to the reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Miransertib binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. This may lead to the reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration. |
|---|---|
| prefLabel | Miransertib
|
| label | Miransertib
|
| PDQ_Closed_Trial_Search_ID | 717768
|
| code | C99172
|
| Has_Target | |
| prefixIRI | NCIT:C99172
|
| in_subset | |
| Preferred_Name | Miransertib
|
| FDA_UNII_Code | T1DQI1B52Y
|
| Contributing_Source | FDA
|
| Maps_To |
Miransertib
AKT Inhibitor ARQ 092
|
| CAS_Registry | 1313881-70-7
|
| NCI_Drug_Dictionary_ID | 717768
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 717768
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C3274586
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |